0. Introduction {#s0005}
===============

Diabetes mellitus (DM) is one of the major chronic non-infectious diseases in the world, and, with a continuous increase in number of patients, the prevalence of DM is also constantly aggravated; thus, DM has brought a much more severe burden to human beings. According to the *Global Report on Diabetes* of World Health Organization (WHO) in 2016, there were 422 million (or 8.5% of the population) in the world suffering from the DM, and DM as well as its complication has been affecting the life quality of human beings, and become an important public health problem. Thus, research and development of Traditional Chinese Medicine (TCM) for effective treatment of DM and its complications are of great application significance ([@b0070]). Curcumin, a kind of diketone compounds extracted from the Curcuma Longa, is quite safe with extensive pharmacological effects, such as anti-inflammation, anti-oxidation, decreasing the blood glucose, immune regulation and anti-proliferation ([@b0075], [@b0010]). A variety of biological effects of curcumin are quite conducive to ameliorating the progression of DM, and thus, curcumin is a kind of natural drug with great potential ([@b0005]). According to the study, it is reported that curcumin can not only protect the pancreatic β cell and increase the sensitivity to insulin ([@b0055]), but also manifest positive significance for treatment of DM complication.

Although the glucose-lowering effect of curcumin has been reported, we have not found any studies reporting the effect of curcumin on the blood glucose levels of type 2 DM rats in different stage of disease, or the effect on the postprandial blood sugar and levels of FFAs and TNF-α in serum. Thus, this study aimed to explore the effect of curcumin, as the active ingredient, on the postprandial blood sugar and the levels of FFAs and TNF-α in different stage of disease in the DM rat models, so as to figure out the characteristics of curcumin in decreasing the blood sugar and the specific mechanism.

1. Materials {#s0010}
============

1.1. Reagent {#s0015}
------------

Total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) (Shanghai High-track Medical Equipment Co., Ltd.); citric acid and sodium citrate (Beijing Taibo Chemical Co., Ltd.); buffer for paraffin-embedding, washing, dilution, substrate (pH = 5.0), tetramethyl benzidine (TMB), and ABTS (Guangzhou Ribobio Co., Ltd.); curcumin (99%; Sinopharm Chemical Reagent Co., Ltd.); streptozotocin (STZ; Sigma, US).

1.2. Instruments {#s0020}
----------------

Roche glucometer (ACCU-CHEK, Roche, Germany); automatic biochemical analyzer (AU2700, Olympus, Japan); electronic scale (Mettler-Toledo, Switzerland).

1.3. Experiment animals {#s0025}
-----------------------

Male specified-pathogens free (SPF) SD rats (weight between 220 and 240 g) were provided by Henan Experiment Animal Center \[SCKK (Yu) 2010--0002\].

2. Methods {#s0030}
==========

2.1. Establishment of animal models ([@b0060], [@b0045]) {#s0035}
--------------------------------------------------------

In 60 SPF SD male rats, 15 were selected randomly as the normal control and received the normal feeding procedure, while remaining rats were fed with the high-fat and -glucose food (cholesterol 1%, yolk powder 3%, lard oil 10%, sucrose 20% and basic food 66%). After 4 weeks of feeding, intraperitoneal injection of STZ (1%; 25 mg/kg) prepared by the citric acid and sodium citrate buffer. Thereafter, high-fat and -glucose feeding procedure lasted for another 4 weeks followed by measurement of the random blood glucose with the glucometer, and random blood glucose ≥16.7 mmol L^−1^ suggested that the model was established successfully.

2.2. Drug intervention {#s0040}
----------------------

In this study, models were successfully established in 30 rats, and these rats were randomly divided into two groups, i.e. the model group (n = 15) and the curcumin group (n = 15), and received the intragastric administration at a dose of 250 mg/kg. Rats in the curcumin group took curcumin, while rats in the normal control group and the model group took normal saline in equivalent volume instead. Intragastric administration was performed once per day, and lasted for 8 weeks. During this period, rats in each group underwent regular feeding.

2.3. Observation indexes and measurement methods {#s0045}
------------------------------------------------

During drug administration, we observed the responses, status and death of rats in each group closely. At the 4th and 8th weeks, blood samples were collected from the caudal vein for detecting the FBG level and the blood glucose levels at 30 min, 60 min and 120 min with the glucometer; as for insulin tolerance test, we detected the FINS level and the blood glucose at 40 min and 90 min; after the last time of drug administration, we collected the blood sample from the arteria cruralis to measure the levels of TC, TG, HDL-C and LDL-C in serum with the automatic biochemical analyzer; in addition, before drug administration and after the last time of drug administration, we assayed the levels of FFA and TNF-α in blood with the automatic biochemical analyzer.

2.4. Statistical analysis {#s0050}
-------------------------

Experiment data were presented as mean ± standard deviation ($\overline{x} \pm s$) and SPSS 17.0 was applied for statistical analysis. As for intergroup comparison, *t* test was adopted. *p* \< .05 suggested that the difference had statistical significance (see [Table 1](#t0005){ref-type="table"}).Table 1General condition of rats in all groups.GroupDiet and activityMental statusSkin and furNormal control groupNormalFineLustrousModel groupDecreasedDispiritedReluster and messyCurcumin groupDecreased in varying degreeFairReluster

3. Results {#s0055}
==========

3.1. General condition of rats {#s0060}
------------------------------

### 3.1.1. Changes in glucose tolerance {#s0065}

From the results of this study, we found that in the same period, the FBG level in the curcumin group was significantly lower than that in the model group, and the difference had statistical significance (*p* \< .05); the blood glucose at 30 min in the curcumin group was also lower than those in the model group and the normal control group, but when it came to the 4th week, the differences had statistical significance (*p* \< .05); the blood glucose at 60 and 120 min was also lower than those in the other two groups, but these differences only had statistical significance until the 4th week (*p* \< .05); at the 8th week, we found that the differences with the model group in the same period also showed statistical significance (*p* \< .05). Compared with the normal control group in the same period, we found that the AUCs of glucose in each group were all significantly increased, and the difference had statistical significance (*p* \< .05). In comparison between the curcumin group and the normal control group, model group in the same period, we found that the AUCs of glucose were decreased in the curcumin group, and the differences had statistical significance (*p* \< .05). All these results suggested that curcumin can lower the blood glucose level in type II DM rat models ([Table 2](#t0010){ref-type="table"}).Table 2Changes in the glucose tolerance of rats at the 4th and 8th weeks after drug administration ($\overline{x} \pm s$).GroupTimeCase (n)Blood glucose0 min30 min60 min120 minAUCNormal control group4th week155.73 ± 0.527.41 ± 0.697.98 ± 0.987.69 ± 0.8222.38 ± 1.128th week155.8 ± 0.78.52 ± 0.678.41 ± 0.797.73 ± 1.2324.13 ± 1.98Model group4th week157.83 ± 2.67[\*](#tblfn1){ref-type="table-fn"}13.73 ± 1.17[\*](#tblfn1){ref-type="table-fn"}14.25 ± 2.63[\*](#tblfn1){ref-type="table-fn"}13.78 ± 2.52[\*](#tblfn1){ref-type="table-fn"}32.65 ± 2.78[\*](#tblfn1){ref-type="table-fn"}8th week1511.99 ± 1.52^\*\*^15.78 ± 2.69[\*](#tblfn1){ref-type="table-fn"}16.18 ± 3.28[\*](#tblfn1){ref-type="table-fn"}15.92 ± 3.96[\*](#tblfn1){ref-type="table-fn"}35.96 ± 4.21[\*](#tblfn1){ref-type="table-fn"}Curcumin group4th week154.83 ± 1.81[\#](#tblfn2){ref-type="table-fn"}10.07 ± 3.61[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}11.76 ± 2.96[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}10.91 ± 3.02[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}28.99 ± 3.92[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}8th week156.96 ± 0.76[\#](#tblfn2){ref-type="table-fn"}11.03 ± 3.51[\*](#tblfn1){ref-type="table-fn"}12.89 ± 2.99[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}11.77 ± 4.12[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}29.97 ± 3.89[\*](#tblfn1){ref-type="table-fn"}^,^[\#](#tblfn2){ref-type="table-fn"}[^1][^2]

3.2. Changes in insulin tolerance {#s0070}
---------------------------------

In the experiment of insulin tolerance test, the results showed that in the same period, the FBG level in the curcumin group was significantly lower than that in the model group, and the difference had statistical significance (*p* \< .05). After subcutaneous injection of insulin, we found that the blood glucose at 40 min and 90 min in the curcumin group was decreased, while AUC of glucose level was also decreased (*p* \< .05 or .01). These results suggested that curcumin can ameliorate the decrease in insulin tolerance and increase the sensitivity to insulin in type II DM rat models ([Table 3](#t0015){ref-type="table"}).Table 3Changes in the insulin tolerance of rats at the 4th and 8th weeks after medication.GroupTimeCase (n)Blood glucose0 min40 min90 minAUCNormal control group4th week156.39 ± 0.974.23 ± 1.094.02 ± 0.939.27 ± 1.188th week155.97 ± 1.124.11 ± 0.994.52 ± 0.699.33 ± 1.09Model group4th week158.99 ± 2.63[\*](#tblfn3){ref-type="table-fn"}7.93 ± 1.56[\*\*](#tblfn11){ref-type="table-fn"}7.17 ± 1.89[\*\*](#tblfn11){ref-type="table-fn"}12.98 ± 2.32[\*\*](#tblfn11){ref-type="table-fn"}8th week1512.01 ± 1.98[\*\*](#tblfn11){ref-type="table-fn"}10.99 ± 1.28[\*\*](#tblfn11){ref-type="table-fn"}10.81 ± 1.85[\*\*](#tblfn11){ref-type="table-fn"}14.92 ± 1.69[\*](#tblfn3){ref-type="table-fn"}Curcumin group4th week155.02 ± 1.58[\#](#tblfn4){ref-type="table-fn"}4.19 ± 0.98[\#\#](#tblfn5){ref-type="table-fn"}4.07 ± 1.77[\#](#tblfn4){ref-type="table-fn"}9.32 ± 1.88[\#](#tblfn4){ref-type="table-fn"}8th week156.89 ± 1.73[\#](#tblfn4){ref-type="table-fn"}4.03 ± 1.51[\#](#tblfn4){ref-type="table-fn"}3.89 ± 1.99[\#](#tblfn4){ref-type="table-fn"}9.23 ± 2.08[\#](#tblfn4){ref-type="table-fn"}[^3][^4][^5][^6]

3.3. Changes in TC, TG, HDL-C and LDL-C in serum {#s0075}
------------------------------------------------

From [Table 4](#t0020){ref-type="table"}, we can see that after 8 weeks of medication, compared with the rats in the normal group, the levels of HDL-C, LDL-C, TC and TG in rats of the model group and the curcumin group were obviously increased (*p* \< .05). In comparison with the model group, the level of LDL-C in rats of the curcumin group was also decreased significantly (*p* \< .05), suggesting that curcumin can decrease the LDL-C level in type II DM rats induced by high-fat food and STZ.Table 4Changes in TC, TG, HDL-C and LDL-C in serum of rats in all groups after 8 weeks of medication.GroupCase (n)HDL-C (mmol/L)LDL-C (mmol/L)TC (mmol/L)TG (mmol/L)Normal control group150.93 ± 0.140.19 ± 0.071.21 ± 0.120.75 ± 0.24Model group151.52 ± 0.44[\*](#tblfn6){ref-type="table-fn"}4.09 ± 3.91[\*](#tblfn6){ref-type="table-fn"}6.61 ± 6.04[\*](#tblfn6){ref-type="table-fn"}1.25 ± 0.49[\*](#tblfn6){ref-type="table-fn"}Curcumin group151.31 ± 0.71[\*](#tblfn6){ref-type="table-fn"}2.95 ± 6.42[\*](#tblfn6){ref-type="table-fn"}^,^[\#](#tblfn7){ref-type="table-fn"}6.35 ± 10.31[\*](#tblfn6){ref-type="table-fn"}1.01 ± 0.47[\*](#tblfn6){ref-type="table-fn"}[^7][^8]

3.4. Changes in FFA and TNF-α in serum {#s0080}
--------------------------------------

In comparison with the normal control group in the same period, we found that the content of FFAs and TNF-α in serum of rats of the model group were elevated significantly, and the differences had statistical significance (*p* \< .05 or .01); the levels in the curcumin group were significantly decreased in comparison with the model group in the same period, and the difference had statistical significance (*p* \< .05 or .01; [Table 5](#t0025){ref-type="table"}). This suggested that curcumin can decrease the levels of FFA and TNF-α in type II DM rats in varying degrees.Table 5Changes in FFA and TNF-α in serum.GroupTimeCase (n)FFA (μmol/L)TNF-α (ng/L)Normal control group4th week15143.98 ± 12.1272.12 ± 11.458th week15167.25 ± 9.8973.98 ± 10.01Model group4th week15189.23 ± 11.56[\*\*](#tblfn12){ref-type="table-fn"}80.25 ± 8.25[\*](#tblfn8){ref-type="table-fn"}8th week15195.56 ± 10.45[\*\*](#tblfn12){ref-type="table-fn"}79.50 ± 11.21[\*](#tblfn8){ref-type="table-fn"}Curcumin group4th week15152.21 ± 5.96[\#](#tblfn9){ref-type="table-fn"}75.93 ± 9.12[\#](#tblfn9){ref-type="table-fn"}8th week15149.99 ± 9.24[\#\#](#tblfn10){ref-type="table-fn"}74.82 ± 8.27[\#](#tblfn9){ref-type="table-fn"}[^9][^10][^11][^12]

4. Discussion {#s0085}
=============

TCM studies have indicated that curcumin is a major active ingredient with the pharmacological effects of anti-oxidation, anti-inflammation and anti-canceration ([@b0050], [@b0090]). However, there remain few studies reporting the role of curcumin in treatment of DM, and the effect of curcumin on glucose and lipid metabolism in type II DM as well as the molecular mechanism have been elusive.

In this study, with the type II DM rats as subjects, these rats were fed with high-fat food for 4 weeks followed by injection of STZ, and after the other 4 weeks of feeding with high-fat food, we screened out the rats with random blood glucose ≥16.7 mmol·L^−1^ as the subjects. Then, the subjects received the intragastric administration of curcumin, and the comparison between the curcumin group and the model group in the same period showed that the FBG, blood glucose at 30, 60 and 120 min and the AUC of glucose were decreased in varying degrees in the curcumin group, and the differences had statistical significance (*p* \< .05). After subcutaneous injection of insulin, we found that the blood glucose at 40 min and 90 min in the curcumin group was decreased, while AUC of glucose level was also decreased (*p* \< .05 or .01), suggesting that curcumin can decrease the blood glucose in type II DM models, and the effect usually appears after 4 weeks of medication.

Through measurement of TC, TG, HDL-C and LDL-C levels in each group, we found that eight weeks after medication, compared with the rats in the normal group, the levels of HDL-C, LDL-C, TC and TG in rats of the model group and the curcumin group were obviously increased (*p* \< .05). In comparison with the model group, the level of LDL-C in rats of the curcumin group was also decreased significantly (*p* \< .05), suggesting that curcumin can decrease the LDL-C level in the type II DM rat models induced by high-fat food and STZ.

Among the majority of patients with obesity, especially those with abdominal obesity, various factors can lead to an increase in visceral fat, among which the role of FFA is quite important ([@b0025]). The mechanism might be ([@b0080], [@b0085], [@b0065]): Under the homeostatic regulation, extra adipose tissues are prone to degradation and metabolism when the activity of LPL is increased, resulting in excessive release of FFA, and leading to or exacerbating the insulin resistance. TNF-α is a kind of cytokine in association with the insulin resistance and type II diabetes mellitus, and mainly secreted by mononuclear macrophage. It has been reported that TNF-α has a variety of functions, e.g. activating the leukocytes, mediating the endotoxic shock, regulating the inflammation and immune responses. TNF-α is highly expressed usually in the adipose cells of human beings or animals with obesity or insulin resistance ([@b0095], [@b0035]), and the mechanism might be that through enhancing the HSL activity and inhibiting the activity of LPL, TNF-α can promote the mobilization of fat and decrease the content of fatty acid, thereby accelerating lipid synthesis. In addition, there is a vicious cycle between the FFA and TNF-α ([@b0030], [@b0040]), i.e. TNF-α can increase the level of FFA in plasma, but FFA can increase the expression of TNF-α through the autophagy-lysosome pathway. Thus, this viscious cycle promote and even exacerbate the insulin resistance ([@b0015]). This process might be realized through promoting the alterations in structure and function of mitochondria, oxidative stress and oxidation and overload of fatty acid.

From this study, we found that treatment with curcumin can ameliorate the disorder in glucose and lipid metabolism, increase the sensitivity to insulin and improve the insulin resistance in type II DM rat models. Meanwhile, the results of this study also revealed that curcumin medication can significantly decrease the levels of FFA and TNF-α in serum of type II DM rat models. Thus, we inferred that the mechanism of curcumin in ameliorating the insulin-resistance might be correlated with the decrease in levels of FFA and TNF-α in serum. The results of this study are expected to enhance the understanding the pathogenesis of DM, and to provide theoretical evidence for discovering the molecular biological mechanism of curcumin in treatment of type II DM.
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